Literature DB >> 21049556

Transient elastography: a non-invasive tool for assessing liver fibrosis in HIV/HCV patients.

Valentina Li Vecchi1, Maurizio Soresi, Claudia Colomba, Giovanni Mazzola, Pietro Colletti, Maurizio Mineo, Paola Di Carlo, Emanuele La Spada, Giovanni Vizzini, Giuseppe Montalto.   

Abstract

AIM: To assess the prevalence of advanced liver fibrosis (ALF) in human immunodeficiency virus (HIV), hepatitis C virus (HCV) and HIV/HCV patients using transient elastography, and to identify factors associated with ALF.
METHODS: Between September 2008 and October 2009, 71 HIV mono-infected, 57 HIV/HCV co-infected and 53 HCV mono-infected patients on regular follow-up at our Center were enrolled in this study. Alcohol intake, the main parameters of liver function, presence of HCV-RNA, HIV-RNA, duration of highly active anti-retroviral therapy (HAART) and CD4 cell count were recorded. ALF was defined as liver stiffness (LS) ≥ 9.5 kPa. To estimate liver fibrosis (LF) a further 2 reliable biochemical scores, aspartate aminotransferase platelet ratio index (APRI) and FIB-4, were also used.
RESULTS: LS values of co-infected patients were higher than in either HIV or HCV mono-infected patients (χ(2)(MH) = 4, P < 0.04). In fact, LS ≥ 9.5 was significantly higher in co-infected than in HIV and HCV mono-infected patients (χ(2) = 5, P < 0.03). Also APRI and the FIB-4 index showed more LF in co-infected than in HIV mono-infected patients (P < 0.0001), but not in HCV mono-infected patients. In HIVHCV co-infected patients, the extent of LS was significantly associated with alcohol intake (P < 0.04) and lower CD4+ cell count (P < 0.02). In HCV patients, LS was correlated with alcohol intake (P < 0.001) and cholesterol levels (P < 0.03). Body mass index, diabetes, HCV- and HIV-viremia were not significantly correlated with LS. In addition, 20% of co-infected patients had virologically unsuccessful HAART; in 50% compliance was low, CD4+ levels were < 400 cells/mm(3) and LS was > 9.5 kPa. There was no significant correlation between extent of LF and HAART exposure or duration of HAART exposure, in particular with specific dideoxynucleoside analogues.
CONCLUSION: ALF was more frequent in co-infected than mono-infected patients. This result correlated with lower CD4 levels. Protective immunological effects of HAART on LF progression outweigh its hepatotoxic effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21049556      PMCID: PMC2975093          DOI: 10.3748/wjg.v16.i41.5225

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  35 in total

1.  Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis.

Authors:  C S Graham; L R Baden; E Yu; J M Mrus; J Carnie; T Heeren; M J Koziel
Journal:  Clin Infect Dis       Date:  2001-07-06       Impact factor: 9.079

2.  The role of laparoscopy in the diagnosis of cirrhosis.

Authors:  J Poniachik; D E Bernstein; K R Reddy; L J Jeffers; M E Coelho-Little; F Civantos; E R Schiff
Journal:  Gastrointest Endosc       Date:  1996-06       Impact factor: 9.427

3.  Percutaneous liver biopsy: a safe outpatient procedure?

Authors:  G Montalto; M Soresi; A Carroccio; F Bascone; S Tripi; F Aragona; G Di Gaetano; A Notarbartolo
Journal:  Digestion       Date:  2001       Impact factor: 3.216

4.  Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance.

Authors:  F Blanco; P Barreiro; P Ryan; E Vispo; L Martín-Carbonero; P Tuma; P Labarga; J Medrano; J González-Lahoz; V Soriano
Journal:  J Viral Hepat       Date:  2011-01       Impact factor: 3.728

5.  Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study.

Authors:  Luz Martín-Carbonero; Yves Benhamou; Massimo Puoti; Juan Berenguer; José Mallolas; Carmen Quereda; Ana Arizcorreta; Antonio Gonzalez; Jurgen Rockstroh; Victor Asensi; Pilar Miralles; Montse Laguno; Leonor Moreno; José Antonio Girón; Martin Vogel; Javier García-Samaniego; Marina Nuñez; Miriam Romero; Santiago Moreno; Juan José de la Cruz; Vincent Soriano
Journal:  Clin Infect Dis       Date:  2003-12-08       Impact factor: 9.079

6.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

Authors:  Chun-Tao Wai; Joel K Greenson; Robert J Fontana; John D Kalbfleisch; Jorge A Marrero; Hari S Conjeevaram; Anna S-F Lok
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

7.  Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus.

Authors:  Carmen Martinez-Sierra; Ana Arizcorreta; Fernando Díaz; Rafael Roldán; Leopoldo Martín-Herrera; Eugenio Pérez-Guzmán; José A Girón-González
Journal:  Clin Infect Dis       Date:  2003-01-31       Impact factor: 9.079

8.  Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies.

Authors:  F Piccinino; E Sagnelli; G Pasquale; G Giusti
Journal:  J Hepatol       Date:  1986       Impact factor: 25.083

9.  Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

Authors:  Laurent Sandrin; Bertrand Fourquet; Jean-Michel Hasquenoph; Sylvain Yon; Céline Fournier; Frédéric Mal; Christos Christidis; Marianne Ziol; Bruno Poulet; Farad Kazemi; Michel Beaugrand; Robert Palau
Journal:  Ultrasound Med Biol       Date:  2003-12       Impact factor: 2.998

10.  Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients.

Authors:  A H Mohsen; P J Easterbrook; C Taylor; B Portmann; R Kulasegaram; S Murad; M Wiselka; S Norris
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

View more
  5 in total

1.  Non invasive tools for the diagnosis of liver cirrhosis.

Authors:  Maurizio Soresi; Lydia Giannitrapani; Melchiorre Cervello; Anna Licata; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

2.  Alcohol Consumption, Progression of Disease and Other Comorbidities, and Responses to Antiretroviral Medication in People Living with HIV.

Authors:  Manuela G Neuman; Michelle Schneider; Radu M Nanau; Charles Parry
Journal:  AIDS Res Treat       Date:  2012-03-11

3.  Latent Class Analysis of Noninvasive Methods and Liver Biopsy in Chronic Hepatitis C: An Approach without a Gold Standard.

Authors:  Flavia F Fernandes; Hugo Perazzo; Luiz E Andrade; Alessandra Dellavance; Carlos Terra; Gustavo Pereira; João L Pereira; Frederico Campos; Maria L Ferraz; Renata M Perez
Journal:  Biomed Res Int       Date:  2017-09-13       Impact factor: 3.411

4.  Abnormal liver stiffness assessed using transient elastography (Fibroscan®) in HIV-infected patients without HBV/HCV coinfection receiving combined antiretroviral treatment.

Authors:  Sang Hoon Han; Seung Up Kim; Chang Oh Kim; Su Jin Jeong; Jun Yong Park; Jun Yong Choi; Do Young Kim; Sang Hoon Ahn; Young Goo Song; Kwang-Hyub Han; June Myung Kim
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

5.  Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study.

Authors:  Emanuele Focà; Massimiliano Fabbiani; Mattia Prosperi; Eugenia Quiros Roldan; Francesco Castelli; Franco Maggiolo; Elisa Di Filippo; Simona Di Giambenedetto; Roberta Gagliardini; Annalisa Saracino; Massimo Di Pietro; Andrea Gori; Laura Sighinolfi; Angelo Pan; Maria Concetta Postorino; Carlo Torti
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.